SAN FRANCISCO and SINGAPORE, Jan. 07, 2025 — Hummingbird Bioscience, a biotherapeutics company specializing in developing innovative treatments for challenging diseases, announced today that it has granted Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on advanced cancer therapies, an exclusive, global license for its monoclonal antibodies targeting a specific, undisclosed protein.
Under the licensing agreement, Immunome will be responsible for research, development, manufacturing, and commercialization. Hummingbird Bioscience will receive an upfront payment and is eligible for future development and sales milestones, as well as royalties.
“This agreement highlights the value of Hummingbird Bioscience’s antibody discovery platform,” said Piers Ingram, PhD, CEO of Hummingbird Bioscience. “We are pleased to partner with Immunome, a company with a proven track record in developing and commercializing novel antibody-drug conjugates (ADCs). Their expertise makes them the ideal partner to advance these antibodies.” He added, “Hummingbird Bioscience remains dedicated to progressing our pipeline of preclinical and clinical-stage therapies to provide patients with transformative treatments for difficult-to-treat diseases.”
Hummingbird Bioscience leverages proprietary AI-driven algorithms, immunization techniques, and Abvantage™ mice to accelerate the discovery of highly specific, high-affinity antibodies. The platform focuses antibody responses on optimal, functionally relevant epitopes; several resulting therapies are in clinical development or have been partnered.
About Hummingbird Bioscience
Hummingbird Bioscience is a precision biotherapeutics company developing groundbreaking biologics for challenging diseases. Addressing limitations of current ADC therapies, Hummingbird Bioscience is creating a pipeline of next-generation ADCs using proprietary antibody discovery and linker/payload technologies. The company’s pipeline includes preclinical ADCs, and novel biologics such as HMBD-001 (anti-HER3 mAb) and HMBD-002 (anti-VISTA mAb) in Phase I, plus an out-licensed ADC (HMBD-501) entering clinical trials in 2025. Hummingbird Bioscience integrates computational and systems biology with experimental drug discovery, spanning from initial discovery through clinical development. This approach optimizes the translation of scientific findings while mitigating risks inherent in drug development. The company is driven by scientific rigor, collaboration, and integrity, accelerating the path from concept to clinic.
For more information, please visit , and follow Hummingbird Bioscience on , , and .
CONTACT: Contacts Media: Crystal Ho c.ho@hummingbirdbio.com media@hummingbirdbio.com +65 6979 5580 Investors: investors@hummingbirdbio.com
